Hepatic Encephalopathy: From the Pathogenesis to the New Treatments

Hepatic encephalopathy is a frequent and serious complication of liver cirrhosis; the pathophysiology of this complication is not fully understood although great efforts have been made during the last years. There are few prospective studies on the epidemiology of this complication; however, it is known that it confers with high short-term mortality. Hepatic encephalopathy has been classified into different groups depending on the degree of hepatic dysfunction, the presence of portal-systemic shunts, and the number of episodes. Due to the large clinical spectra of overt EH and the complexity of cirrhotic patients, it is very difficult to perform quality clinical trials for assessing the efficacy of the treatments proposed. The physiopathology, clinical manifestation, and the treatment of HE is a challenge because of the multiple factors that converge and coexist in an episode of overt HE.

• Publication year

  2014

• Venue

  ISRN Hepatology

• Publication date

  2014-06-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2014/236268PMID 27335836PMCID 4890879
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy

  2014cited by this paper
• Brain Magnetic Resonance Spectroscopy in Episodic Hepatic Encephalopathy

  2013cited by this paper
• Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?

  2013cited by this paper
• Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

  2013cited by this paper
• Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study.

  2013cited by this paper
• Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute‐on‐chronic liver failure: The RELIEF trial

  2013cited by this paper
• Falls and cognitive dysfunction impair health-related quality of life in patients with cirrhosis

  2013cited by this paper
• Safety of Ornithine Phenylacetate in Cirrhotic Decompensated Patients: An Open-label, Dose-escalating, Single-cohort Study

  2013cited by this paper
• Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow, not increased ammonia uptake

  2013influential reference
• Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: A multicenter survey on safety and efficacy

  2013cited by this paper
• Meta-analysis: the diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy

  2013cited by this paper
• Systemic inflammation and ammonia in hepatic encephalopathy

  2013cited by this paper
• Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.

  2012cited by this paper
• Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure.

  2012cited by this paper
• Randomised clinical trial: rifaximin improves health‐related quality of life in cirrhotic patients with hepatic encephalopathy – a double‐blind placebo‐controlled study

  2011cited by this paper
• Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy. A comparative study of 154 patients with liver disease

  2011cited by this paper
• Rifaximin in the treatment of hepatic encephalopathy

  2011cited by this paper
• Effects of Branched-Chain Amino Acids Supplementation in Patients With Cirrhosis and a Previous Episode of Hepatic Encephalopathy: A Randomized Study

  2011cited by this paper
• New assessment of hepatic encephalopathy.

  2011cited by this paper
• Review article: the modern management of hepatic encephalopathy

  2010cited by this paper
• Altered glial-neuronal crosstalk: cornerstone in the pathogenesis of hepatic encephalopathy.

  2010cited by this paper
• Rifaximin treatment in hepatic encephalopathy.

  2010cited by this paper
• Variations in the Promoter Region of the Glutaminase Gene and the Development of Hepatic Encephalopathy in Patients With Cirrhosis

  2010cited by this paper
• Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis

  2010cited by this paper
• Hepatic encephalopathy.

  2009cited by this paper
• Hyponatremia Is a Risk Factor of Hepatic Encephalopathy in Patients With Cirrhosis: A Prospective Study With Time-Dependent Analysis

  2009cited by this paper
• Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis

  2008cited by this paper
• Actualización en el tratamiento de la encefalopatía hepática

  2008cited by this paper
• Hepatic Encephalopathy

  2008cited by this paper
• [Update on the management of hepatic encephalopathy].

  2008cited by this paper
• Pathogenetic mechanisms of hepatic encephalopathy

  2008cited by this paper
• Development of a clinical hepatic encephalopathy staging scale

  2007cited by this paper
• L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.

  2007cited by this paper
• Glutamine: A Trojan horse in ammonia neurotoxicity

  2006cited by this paper
• Neuropsychological abnormalities in cirrhosis include learning impairment.

  2006cited by this paper
• Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations.

  2005cited by this paper
• In vivo imaging of cerebral “peripheral benzodiazepine binding sites” in patients with hepatic encephalopathy

  2005cited by this paper
• Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study

  2005cited by this paper
• Gastrointestinal bleeding: don’t overlook the role of the pancreas

  2005cited by this paper
• Oral administration of sildenafil restores learning ability in rats with hyperammonemia and with portacaval shunts

  2005cited by this paper
• Increased brain concentrations of a neuroinhibitory steroid in human hepatic encephalopathy

  2005cited by this paper
• Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.

  2005cited by this paper
• Regional differences in cerebral blood flow and cerebral ammonia metabolism in patients with cirrhosis

  2004cited by this paper
• Infection, inflammation and hepatic encephalopathy, synergism redefined.

  2004influential reference
• Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy

  2004cited by this paper
• Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

  2004cited by this paper
• Normal protein diet for episodic hepatic encephalopathy: results of a randomized study.

  2004cited by this paper
• Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid.

  2004cited by this paper
• Minimal hepatic encephalopathy impairs fitness to drive

  2004cited by this paper
• Pathophysiology of Hepatic Encephalopathy: A New Look at GABA from the Molecular Standpoint

  2004cited by this paper
• Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy.

  2003cited by this paper
• Hemoglobin metabolites mimic benzodiazepines and are possible mediators of hepatic encephalopathy.

  2003cited by this paper
• Mini-asterixis in hepatic encephalopathy induced by pathologic thalamo-motor-cortical coupling

  2003cited by this paper
• The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis

  2003cited by this paper
• Bradykinesia in minimal hepatic encephalopathy is due to disturbances in movement initiation.

  2003cited by this paper
• Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study.

  2003cited by this paper
• Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

  2003cited by this paper
• Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial.

  2003cited by this paper
• Critical flicker frequency for quantification of low‐grade hepatic encephalopathy

  2002cited by this paper
• Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998

  2002cited by this paper
• Neuropsychological characterization of hepatic encephalopathy.

  2001cited by this paper
• Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients.

  2001cited by this paper
• Magnetic resonance imaging and proton spectroscopic alterations correlate with parkinsonian signs in patients with cirrhosis.

  2000cited by this paper
• Hepatic encephalopathy: a neuropsychiatric disorder involving multiple neurotransmitter systems

  2000cited by this paper
• Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?

  2000cited by this paper
• Partial pressure of ammonia versus ammonia in hepatic encephalopathy

  2000cited by this paper
• Cerebral herniation in patients with acute E liver failure is correlated with arterial ammonia concentration

  1999cited by this paper
• Pathophysiology of cerebral edema in fulminant hepatic failure.

  1999cited by this paper
• Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure.

  1999cited by this paper
• Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction.

  1999cited by this paper
• Chronic hyponatremia exacerbates ammonia-induced brain edema in rats after portacaval anastomosis.

  1998cited by this paper
• Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: An italian multicenter double‐blind, placebo‐controlled, cross‐over study

  1998cited by this paper
• Bright basal ganglia in T1-weighted magnetic resonance images are frequent in patients with portal vein thrombosis without liver cirrhosis and not suggestive of hepatic encephalopathy.

  1998cited by this paper
• Cerebral oedema and increased intracranial pressure in chronic liver disease.

  1998cited by this paper
• Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

  1997cited by this paper
• The hyperventilation of cirrhosis: Progesterone and estradiol effects

  1997cited by this paper
• Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis.

  1997cited by this paper
• ESPEN guidelines for nutrition in liver disease and transplantation.

  1997cited by this paper
• Cerebral circulation in liver failure: Ohm's law in force.

  1996cited by this paper
• Astrocytic-Ammonia Interactions in Hepatic Encephalopathy

  1996cited by this paper
• Cerebral Circulation in Liver Failure: Ohm's Law in Force

  1996cited by this paper
• Subclinical Hepatic Encephalopathy

  1996cited by this paper
• [Subclinical hepatic encephalopathy].

  1996cited by this paper
• Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure

  1996cited by this paper
• Neuropsychological characterization and detection of subclinical hepatic encephalopathy.

  1996cited by this paper
• Natural benzodiazepines and hepatic encephalopathy.

  1996cited by this paper
• Neuropsychiatric profile and hyperintense globus pallidus on T1-weighted magnetic resonance images in liver cirrhosis.

  1996cited by this paper
• Brain Edema and Hepatic Encephalopathy

  1996influential reference
• The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis

  1996cited by this paper
• Noninvasive Neuroinvestigation in Liver Disease

  1996cited by this paper
• Chronic portosystemic hepatic encephalopathy refractory to medical treatment successfully reversed by liver transplantation

  1995cited by this paper
• Increased signals seen in globus pallidus in T1‐weighted magnetic resonance imaging in cirrhotics are not suggestive of chronic hepatic encephalopathy

  1995cited by this paper
• Subclinical hepatic encephalopathy: the diagnostic value of evoked potentials.

  1995cited by this paper
• Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy.

  1995cited by this paper
• Hepatic myelopathy: a rare complication of portacaval shunt.

  1994cited by this paper
• Effect of intrahepatic portal‐systemic shunting on hepatic ammonia extraction in patients with cirrhosis

  1994cited by this paper
• Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy

  1994cited by this paper
• Difficult Management Problems in Fulminant Hepatic Failure

  1993cited by this paper
• Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

  1993cited by this paper
• Rifaximin in the treatment of chronic hepatic encephalopathy.

  1993cited by this paper

• Hepatic Encephalopathy in the Hepato-Gastroenterology and Internal Medicine Department of General Idrissa Pouye Hospital: A Retrospective Prognostic Study of 69 Cases

  2025cites this paper
• Advances in Factors and Risk Prediction of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt

  2025cites this paper
• Absence of Pupillary Reflexes in Pediatric Acute Liver Failure and Neurological Outcome After Liver Transplantation

  2025cites this paper
• PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease.

  2024cites this paper
• Role of fecal microbiota transplant in management of hepatic encephalopathy: Current trends and future directions

  2024cites this paper
• Anaesthesia management for liver transplantation: A narrative review

  2023influential citation
• Frequency of Upper Gastrointestinal Bleeding As Precipitant of Hepatic Encephalopathy among Patients with Liver Cirrhosis

  2022cites this paper
• COVID-19 and Hepatic Encephalopathy: A Narrative Review

  2022cites this paper
• Effect of Helicobacter Pylori Eradication on Hepatic Encephalopathy in Egyptian Cirrhotic Patients

  2022cites this paper
• The importance of electroencephalography in the diagnosis of hepatic encephalopathy due to cirrhosis – a case report

  2022cites this paper
• Hepatic Encephalopathy by Manganese Deposition: A Case Report and a Review of Literature.

  2022cites this paper
• Gut–liver–brain axis in chronic liver disease with a focus on hepatic encephalopathy

  2021cites this paper
• Redefining Success After Liver Transplantation: From Mortality Toward Function and Fulfillment

  2021cites this paper
• Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis

  2021cites this paper
• Hyponatremia and Its Correlation With Hepatic Encephalopathy and Severity of Liver Disease

  2021cites this paper
• Use of Probiotics as a Prophylaxis for Hepatic Encephalopathy: A Review Article

  2021cites this paper
• Ammonia inhibits energy metabolism in astrocytes in a rapid and glutamate dehydrogenase 2-dependent manner

  2020cites this paper
• Efficacy And Safety Of Sodium Benzoate In The Management Of Hyperammonemia in Decompensated Chronic Liver Disease of the Childhood- A Double Blind Randomised Controlled Trial.

  2020cites this paper
• Nursing Management of Hepatic Encephalopathy

  2020influential citation
• Fibroblast Growth Factor–21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells

  2020cites this paper
• Non-Lactulose Medication Therapies for the Management of Hepatic Encephalopathy: A Literature Review

  2020cites this paper
• CIGB-258, An Immunomodulatory Peptide for the Treatment of a COVID-19-associated Hepatic Encephalopathy: A Case Report

  2020cites this paper
• Ammonia inhibits energy metabolism in astrocytes in a rapid and GDH2-dependent manner

  2019cites this paper
• Hepatic Encephalopathy: Pathogenesis and Treatment Strategies

  2019cites this paper
• Iron and manganese-related CNS toxicity: mechanisms, diagnosis and treatment

  2019cites this paper
• The Aging of Iron Man

  2018cites this paper
• Acute Liver Failure

  2018cites this paper
• Regression of Asymmetric Upper Extremity Tremor after Liver Transplantation in a Patient with Hepatic Encephalopathy: Case Report

  2018cites this paper
• Changes in Cerebral Hemodynamics in Patients With Cirrhosis After Liver Transplantation

  2018cites this paper
• Multimodal MR imaging in hepatic encephalopathy: state of the art

  2018cites this paper
• Biological Activities of Lactose-Derived Prebiotics and Symbiotic with Probiotics on Gastrointestinal System

  2018cites this paper
• Neurological disorders in liver transplant candidates: Pathophysiology and clinical assessment.

  2017cites this paper
• Asterixis

  2016cites this paper
• Thioacetamide-Induced Liver Cirrhosis Alters Oxidative Stress Balance and Induces Mitochondrial Respiratory Chain Inhibition in the Brain of Cirrhotic Rats.

  2016cites this paper
• FEATURES OF PHARMACOTHERAPY OF HEPATIC ENCEPHALOPATHY MANIFESTATIONS IN LIVER CIRRHOSIS

  2015cites this paper
• PET and MR imaging of neuroinflammation in hepatic encephalopathy

  2015cites this paper
• World Journal of Hepatology

  year unknowncites this paper